AERD Flashcards

1
Q

Definition of AERD

A

Asthma, nasal polyps, chronic rhinitis and sensitizations to ASA or CoX1 inhibitors which manifests in 30 minutes to 3 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Samter’s triad

A

Aspirin sensitivity, nasal polyp and asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prevalence of AERD in severe asthma

A

7% in mild asthma

14% in severe asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pathophysiology of AERD (not well understood!)

A

Arachidonic acid pathway

  • COX-1 and COX2 –> PGD2 and PGE2
  • Lipoxygenase

People with AERD have imbalance in pathway and more infiltration of eos and mast cells and more release of leukotrines and imbalance of prostoglandin production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Clinic symptoms of AERD

A
  • age 20-50s most common
  • long standing rhinitis
  • Anosmia is a main feature
  • mucosal thickening on CT scans
  • sensitivity to asa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Type 1 NSAID rxn

A

induced asthma and rhino sinusitis
most common
non ige mediated
rhinitis with asa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Type 2 NSAID reaction

A

patients with CSU
presents with urticaria and/or angioedema
non ige mediated
occurs with multiple NSAIDs

NB- Type 1-4 all occur with multiple NSAIDs
Type 5 is usually Ibu (single NSAID)
Type 6 is usually ASA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Type 3 AERD is what type of reaction

A

non ige mediated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Has Asa anaphylaxis ever been reported?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diagnosis of AERD

A
  1. Clinically with history - asthma, nasal polyps, and asa sensitivities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Indications for ASA desensitizations

A
  1. Nasal polyps refractory to other therapies bc chronic asa can slow the rate of nasal polyps
  2. asa- anti plts therapy in CVS patients
  3. NSAIDs are needed for an inflammatory condition (arthritis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Contraindications for ASA desensitization

A
  1. FEV1 < 70% and <1.5 L
  2. Acute coronary syndromes?
  3. Pregnancy
  4. Previous GI bleed?
  5. Patient is on a BB?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Premed for ASA desensitizations

A
  1. Monteleukast 10 mg for 3 days prior - this will control the LRT symptoms, but they will still have UR sx (runny nose, itchy eyes etc)
  2. INCS, and ICS/Laba should be continued
  3. AH should be held for a week
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How long does the ASA challenge take?

A

Always book 3 hours bc symptoms appear within 30 minutes to 3 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ASA Challenge steps

A
  1. Starting dose ~40.5 mg of Asa (40, 80, 120, 160)
  2. Most protocols go with doubling doses of Asa
  3. The dose that provokes symptoms should be repeated after the symptoms are treated
  4. Baseline spiro should be conducted at the start and throughout the challenge
  5. Tx the symptoms - Nasal decongestant, AH, Epi, Antacids
  6. Goal is 325 mg BID or 650 BID
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ASA Challenge steps

A
  1. Starting dose ~40.5 mg of Asa (40, 80, 120, 160)
  2. Most protocols go with doubling doses of Asa
  3. The dose that provokes symptoms should be repeated after the symptoms are treated
  4. Baseline spiro should be conducted at the start and throughout the challenge
  5. Tx the symptoms - Nasal decongestant, AH, Epi, Antacids
  6. Goal is 325 mg BID or 650 BID
17
Q

what is the refractory period after asa desensitization?

A

3-5 days

If so stop your asa for more than 5 days you need to undergo desensitization again

18
Q

Dupilumab MOA

A

blocks IL4 and IL13 which blocks migrations of Eos to the blood stream/ site of inflammation

19
Q

Dupilumab MOA

A

blocks IL4 and IL13 which blocks migrations of Eos to the blood stream/ site of inflammation.

Has shown improvement in polyps and asthma

20
Q

What is the most common SE of Dupi?

A

Conjunctivitis

21
Q

Dupilumab can trigger what condition?

A

EGPA

22
Q

Pathophysiology of AERD

A
  • mechanism is unclear
  • may be related to inhibition of an enzyme COX with subsequent shunting of arachidonic acid metabolism to the lipoxygenase pathway, culminating in a massive leukotriene release